Discovery and Characterization of CBL-B Intramolecular Glue Inhibitors That Increase T Cell Activation and Suppress Tumor Growth By webmaster / April 22, 2026
First-in-Class CBL-B Inhibitor NX-1607: Phase 1a Data in Patients with Advanced Solid Tumors By webmaster / October 18, 2025
Small Molecule Inhibition Of The Ubiquitin Ligase CBL-B With NX-1607 Results In Potent T And NK Cell Mediated Anti-Tumor Response By aterrado@waterhousebrands.com / January 7, 2025
Initial Clinical Characterization Of Novel Proximal Biomarkers For NX-1607, A First-In-Class Oral CBL-B Inhibitor, In Patients With Advanced Malignancies By aterrado@waterhousebrands.com / January 7, 2025
NX-1607, A Small Molecule Inhibitor Of The CBL-B E3 Ubiquitin Ligase, Promotes T And NK Cell Activation And Enhances NK-Mediated ADCC In A Mouse Lymphoma Tumor Model By aterrado@waterhousebrands.com / January 7, 2025
NX-1607, A Small Molecule Inhibitor Of CBL-B, Is Efficacious As A Single Agent And In Combination With Rituximab In Preclinical Mouse Models Of Lymphoma By aterrado@waterhousebrands.com / January 7, 2025
NX-1607, A Small Molecule Inhibitor Of CBL-B, Enhances Anti-PD-1-Mediated Tumor Growth Inhibition By Reshaping Intratumoral Innate And Adaptive Immune Responses By aterrado@waterhousebrands.com / January 7, 2025
NX-1607: A First-In-Class Inhibitor Of Casitas B-Lineage Lymphoma B (CBL-B) For Immuno-Oncology By aterrado@waterhousebrands.com / January 7, 2025
Rational Discovery Of A Small Molecule Intramolecular Glue Inhibitor Of CBL-B That Enhances T-Cell Function By aterrado@waterhousebrands.com / January 7, 2025
